Personalized Support

Powered by nurses

Mom and son discuss the Skytrofa Auto-Injector with a Nurse Advocate

To speak with a member of our support team, please call 1-844-442-7236 or start a chat now (available from 8 AM to 8 PM ET, Monday through Friday)

GET STARTED

Meet the dedicated support team

To contact us, please call 1-844-442-7236

Nurse Advocate

Provides overall case management
Completes insurance verification
Assists with prior authorization and appeal support
Can initiate FastStart fulfillment
Ships Auto-Injector directly to patients
Offers co-pay assistance
Provides ongoing patient support

Field Reimbursement
Manager

Provides case assistance and support through the insurance submission process (prior authorization/appeal)
Offers a local and regional market access reimbursement overview to you and your office
Reviews the Ascendis Signature Access Program^® (A·S·A·P) process, including collaboration with a Nurse Advocate partner
Provides ongoing reimbursement support

Clinical Educator

Schedules virtual or in-person injection training
Trains your patients on how to use their device
Provides ongoing injection support

A·S·A·P is with your patients every step of the way

START HERE

Enrollment confirmed

SMN form is submitted to A·S·A·P

Patient’s case is created in our system

Complete the SMN form here

Benefits verification completed

Summary of Benefits is received and reviewed by your office
Patient receives Welcome Call from the assigned Nurse Advocate

Patient Consent form is confirmed during the Welcome Call

Insurance authorization approved

Prior authorization, plan formulary exception, or appeal submission complete

Your FRM is a valuable resource to use when navigating submissions and appeals

AFTER APPROVAL

Auto-Injector shipped directly to patients

The Auto-Injector is available only through A·S·A·P enrollment

Injection training completed by Clinical Educator

Training scheduled after Auto-Injector shipment
HCP notified upon training completion

The office may be trained by the Clinical Educator team if the HCP prefers to train their patients

Triage Specialty Pharmacy for prescription fulfillment

Review Co-Pay Program with eligible patients

Coverage denial and appeal submission

In the event of a denial, submit an appeal
You may receive more than one denial before approval

Reach out to A·S·A·P or your FRM to see what additional resources are available

FastStart enrollment and approval The FastStart Program is available for commercially insured patients navigating a denied coverage determination or appeals*

SKYTROFA Auto-Injector shipment occurs within 7 business day of FastStart approval
Injection training scheduled and completed by Clinical Educator
HCP notified of training completion

Insurance authorization approved

Prior authorization, plan formulary exception, or appeal submission complete

The A·S·A·P program provides patient support services to eligible patients who were prescribed SKYTROFA for its approved indication.

Guide to Starting Patients on SKYTROFA

Download an overview of the A·S·A·P patient initiation process

Authorization Submission Checklist

Review important submission criteria that insurance companies may request

FastStart Program

The FastStart Program is available for commercially insured patients experiencing a delay in treatment due to denied coverage determination or appeals, who have an open active-insurance authorization*

*Patients are not eligible if they participate in any federal or state healthcare program.

Co-Pay Program for SKYTROFA^®

Eligible patients pay as little as $5 per monthly prescription with no monthly cap and an annual maximum cap of $6000 per calendar year*

A·S·A·P offers eligible patients help accessing treatment. For full terms and conditions and eligibility criteria, click here

*Terms & Conditions apply. See Eligibility and Restrictions.

To learn more about starting your patients, call 1-844-442-7236 to speak with a member of our support team or chat live (available from 8 AM to 8 PM ET, Monday through Friday)

A·S·A·P CHAT

Questions about coverage for your patients?

Get an individualized coverage summary for SKYTROFA

EXPLORE COVERAGE

"The A·S·A·P program has been really supportive. The nurse was helpful and followed up when she said she would. She let us ask as many questions as we had and we could reach her if needed."

— Kylene, SKYTROFA Caregiver Ambassador

HEAR FROM MORE PARENTS

	SKYTROFA^® 0.24 mg hGH/kg/week	Daily somatropin^† 0.24 mg hGH/kg/week	Total
	(n = 105)	(n = 56)	(N = 161)
Male, n (%)	86 (82)	46 (82)	132 (82)
White, n (%)	100 (95.2)	52 (92.9)	152 (94.4)
Chronological age (year)	8.5 ± 2.7	8.5 ± 2.8	8.5 ± 2.7
Bone age (year)	5.8 ± 2.6	6.0 ± 2.7	5.9 ± 2.6
Bone age/chronological age (ratio)	0.69 ± 0.16	0.70 ± 0.14	0.69 ± 0.15
Weight (kg)	21.0 ± 6.5	21.2 ± 6.7	21.1 ± 6.6
BMI (kg/m²)	16.1 ± 1.8	16.5 ± 2.2	16.2 ± 1.9
Height (cm)	112.9 ± 14.1	112.2 ± 15.3	112.7 ± 14.5
Height (SDS)	–2.89 ± 0.85	–3.00 ± 0.90	–2.93 ± 0.87
Historical growth rate (cm/year)^‡	3.9 ± 2.0	3.9 ± 1.7	3.9 ± 1.9
IGF-1 SDS	–2.08 ± 0.88	–1.96 ± 0.98	–2.04 ± 0.92

SKYTROFA^®
0.24 mg hGH/kg/week

Daily somatropin^†
0.24 mg hGH/kg/week

Total

(n = 105)

(n = 56)

(N = 161)

Male, n (%)

86 (82)

46 (82)

132 (82)

White, n (%)

100 (95.2)

52 (92.9)

152 (94.4)

Chronological age (year)

8.5 ± 2.7

8.5 ± 2.8

8.5 ± 2.7

Bone age (year)

5.8 ± 2.6

6.0 ± 2.7

5.9 ± 2.6

Bone age/chronological age (ratio)

0.69 ± 0.16

0.70 ± 0.14

0.69 ± 0.15

Weight (kg)

21.0 ± 6.5

21.2 ± 6.7

21.1 ± 6.6

BMI (kg/m²)

16.1 ± 1.8

16.5 ± 2.2

16.2 ± 1.9

Height (cm)

112.9 ± 14.1

112.2 ± 15.3

112.7 ± 14.5

Height (SDS)

–2.89 ± 0.85

–3.00 ± 0.90

–2.93 ± 0.87

Historical growth rate (cm/year)^‡

3.9 ± 2.0

3.9 ± 1.7

3.9 ± 1.9

IGF-1 SDS

–2.08 ± 0.88

–1.96 ± 0.98

–2.04 ± 0.92

Baseline demographics and clinical characteristics	Total enrolled	Previously treated
	N = 146	n = 143
Male, n (%)	110 (75.3)	109 (76.2)
White, n (%)	124 (84.9)	121 (84.6)
Hispanic or Latino, n (%)	10 (6.8)	10 (7.0)
Mean chronological age (year)	10.6	10.8
BMI SDS, mean (SD)	–0.3 (1.1)	–0.24 (1.06)
Height SDS, mean (SD)	–1.42 (0.84)	–1.40 (0.83)
Tanner stage, n (%)
I	95 (65.1)	92 (64.3)
II	14 (9.6)	14 (9.8)
III	30 (20.5)	30 (21.0)
IV	7 (4.8)	7 (4.9)
IGF‑1 SDS, mean (SD)	0.85 (1.29)	0.91 (1.25)
Daily somatropin dose at trial enrollment (mg hGH/kg/week)	n/a	0.29 (0.05)
Daily somatropin dose duration since treatment initiation (years)	n/a	1.14 (0.73)

Baseline demographics and clinical characteristics

Total enrolled

Previously treated

N = 146

n = 143

Male, n (%)

110 (75.3)

109 (76.2)

White, n (%)

124 (84.9)

121 (84.6)

Hispanic or Latino, n (%)

10 (6.8)

10 (7.0)

Mean chronological age (year)

10.6

10.8

BMI SDS, mean (SD)

–0.3 (1.1)

–0.24 (1.06)

Height SDS, mean (SD)

–1.42 (0.84)

–1.40 (0.83)

Tanner stage, n (%)

95 (65.1)

92 (64.3)

14 (9.6)

14 (9.8)

III

30 (20.5)

30 (21.0)

7 (4.8)

7 (4.9)

IGF‑1 SDS, mean (SD)

0.85 (1.29)

0.91 (1.25)

Daily somatropin dose at trial enrollment (mg hGH/kg/week)

n/a

0.29 (0.05)

Daily somatropin dose duration since treatment initiation (years)

n/a

1.14 (0.73)

	Full analysis set	Treatment completers*
	(N = 298)	(n = 81)^†
Age, years, mean (SD)	10.3 (3.4)	13.3 (1.8)
Sex, male, n (%)	235 (78.9)	66 (81.5)
Height SDS, mean (SD)	–1.6 (0.9)	–1.6 (0.7)
IGF‑1 SDS, mean (SD)	1.0 (1.3)	0.8 (1.5)
Tanner stage, n (%)
Stage I	214 (71.8)	22 (30.1)
Stage II	40 (13.4)	17 (23.3)
Stage III	25 (8.4)	28 (38.4)
Stage IV	16 (5.4)	6 (8.2)
Stage V	3 (1.0)	0

Full analysis set

Treatment completers*

(N = 298)

(n = 81)^†

Age, years, mean (SD)

10.3 (3.4)

13.3 (1.8)

Sex, male, n (%)

235 (78.9)

66 (81.5)

Height SDS, mean (SD)

–1.6 (0.9)

–1.6 (0.7)

IGF‑1 SDS, mean (SD)

1.0 (1.3)

0.8 (1.5)

Tanner stage, n (%)

Stage I

214 (71.8)

22 (30.1)

Stage II

40 (13.4)

17 (23.3)

Stage III

25 (8.4)

28 (38.4)

Stage IV

16 (5.4)

6 (8.2)

Stage V

3 (1.0)

Personalized Support

Powered by nurses

Meet the dedicated support team

A·S·A·P is with your patients every step of the way

Guide to Starting Patients on SKYTROFA

Authorization Submission Checklist

"The A·S·A·P program has been really supportive. The nurse was helpful and followed up when she said she would. She let us ask as many questions as we had and we could reach her if needed."

US Healthcare Professionals

Patient baseline demographics2*

A broad range of patients enrolled in the 26-week clinical trial1

Patient baseline characteristics2

Patient baseline demographics²*

A broad range of patients enrolled in the 26-week clinical trial¹

Patient baseline characteristics²